Zobrazeno 1 - 10
of 16 171
pro vyhledávání: ''
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Autor:
Foteinos-Ioannis Dimitrakopoulos, Kyriaki Papadopoulou, Dimitrios Pectasides, Anna Batistatou, Kitty Pavlakis, George Fountzilas, Helen P. Kourea, Sofia Chrisafi, George Pentheroudakis, Vassiliki Kotoula, Pavlos Papakostas, Eleni Galani, Eleni Res, Dimitrios Bafaloukos, Angelos Koutras, Georgia-Angeliki Koliou, Mattheos Bobos, Kyriakos Chatzopoulos, Anthoula Asimaki-Vlachopoulou
Publikováno v:
Cancer Research and Treatment. 54:1053-1064
Purpose Angiogenesis is a crucial phenomenon in the development and progression of breast cancer (BC), but the clinical significance of angiogenesis-related proteins in metastatic BC remains unknown. This study investigates the prognostic value of va
Autor:
Daniel Moj, Nicola Ammer, Babette Aicher, Jan-Georg Wojtyniak, Thorsten Lehr, Michael Teifel, Herbert Sindermann, Hannah Britz, Nina Hanke
Zoptarelin doxorubicin is a fusion molecule of the chemotherapeutic doxorubicin and a luteinizing hormone-releasing hormone receptor (LHRHR) agonist, designed for drug targeting to LHRHR positive tumors. The aim of this study was to establish a physi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c5e9a18956370d7aca5ee1061fd910
Autor:
Emmanuelle Bompas, Geraldine Martineau, Remy Delva, Isabelle Borget, Stéphane Culine, Giulia Baciarello, Groupe d’Etude des Tumeurs Uro-Genitales (Getug)., Charlotte Greilsamer, Philippe Barthélémy, Raffaele Ratta, Mathilde Deblock, Karim Fizazi, Florence Joly, Gwenaelle Gravis, Philippe Beuzeboc, Caroline Cheneau, J. F. Berdah, Youssef Tazi, Thierry Nguyen Tan Hon, Marine Gross-Goupil, Aude Flechon, Aline Maillard
Publikováno v:
European Urology. 81:234-240
Background The taxanes docetaxel and cabazitaxel prolong overall survival for men with metastatic castration-resistant prostate cancer (mCRPC), with cabazitaxel approved in the postdocetaxel setting only. Recent data suggest they have similar efficac
Autor:
Jeff P. Sharman, Peter Trask, Yeung-Chul Mun, Anthony Masaquel, Habte A. Yimer, Alexey V. Danilov, John M. Burke, Sunil Babu, Jia Li, Michael Boxer
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:121-128
Introduction: Longitudinal changes in health-related quality of life (HRQoL) are important in patients with chronic lymphocytic leukemia (CLL). GIBB (NCT02320487) is an open-label, single-arm phase II study of obinutuzumab (GA101; G) in combination w
Autor:
Julie Means-Powell, Luis Del Valle, Vandana G. Abramson, Claudia Sorrentino, Melinda Sanders, Ingrid A. Mayer, Debra A. Tonetti, Roohi Ismail-Khan, Samarpan Majumder, Richard M Lush, Lucio Miele
Publikováno v:
Clin Breast Cancer
Preclinical studies have demonstrated a complex cross-talk between Notch and estrogen signaling in ERα-positive breast cancer. Gamma-secretase inhibitors (GSIs) are investigational agents that block the cleavage and activation of Notch receptors. In
Autor:
Vincenzo Di Nunno, Laurence Albiges, Axelle Benchimol-Zouari, Laure Hirsch, Bernard Escudier, Annalisa Guida, L. Cerbone, Lucia Carril Ajuria, Flore Salviat, Ronan Flippot, Emeline Colomba, Carolina Alves Costa Silva
Publikováno v:
Clinical Genitourinary Cancer. 20:80-87
Background Cabozantinib, a potent multi-tyrosine kinases inhibitor (TKI), has demonstrated overall survival (OS) benefit over everolimus in patients previously treated with VEGFR TKI for metastatic Renal Cell Carcinoma (mRCC). The efficacy of systemi
Autor:
Yih-Leong Chang, Chiau-Jing Jung, Song-Chou Hsieh, Lo Chiao, Yi-Ming Huang, Chen-Han Chang, Ching-Hung Lin, Yu Min Kuo
Publikováno v:
Breast, Vol 61, Iss, Pp 35-42 (2022)
The Breast : Official Journal of the European Society of Mastology
The Breast : Official Journal of the European Society of Mastology
Targeted therapies against human epidermal growth factor receptor 2 (HER2) are associated with increased interstitial lung disease (ILD). Trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine have markedly extended HER2 breast cancer survival
Autor:
Ryan C. Gimple, Guoxin Zhang, Linjie Zhao, Leo J.Y. Kim, Jia Z. Shen, Cheryl Kim, Briana C. Prager, Xujun Wang, Jean A. Bernatchez, Xiang-Dong Fu, Jeremy N. Rich, Kailin Yang, Jair L. Siqueira-Neto, Deobrat Dixit, Zhixin Qiu, Lukas Chavez, Zhe Zhu, Deguan Lv, Ye Zheng, Denise Hinz, Zhengyu Liang, Charles Spruck, Xiuxing Wang, Chunyu Jin, Qiyuan Yang, Qiulian Wu, Lihua Min, Katherine A. Jones, Zhen Dong, Shruti Bhargava
Publikováno v:
Cancer Discov
Glioblastoma (GBM) is the most lethal primary brain cancer characterized by therapeutic resistance, which is promoted by GBM stem cells (GSC). Here, we interrogated gene expression and whole-genome CRISPR/Cas9 screening in a large panel of patient-de